<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>6109</id>
    <completedYear/>
    <publishedYear>2024</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>19</pageNumber>
    <edition/>
    <issue>5</issue>
    <volume>19</volume>
    <type>article</type>
    <publisherName>Public Library of Science (PLoS)</publisherName>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Single German centre experience with patient journey and care-relevant needs in amyloidosis: The German AMY-NEEDS research and care program</title>
    <abstract language="eng">Background&#13;
Amyloidosis is a rare multi-system disorder associated with frequently delayed diagnosis, enormous disease burden and psychosocial distress.&#13;
&#13;
&#13;
Methods&#13;
Systematic assessment of needs was performed by a subtype-spanning questionnaire-based survey within the AMY-NEEDS research and care program.&#13;
&#13;
&#13;
Results&#13;
118 patients with proven amyloidosis (62.7% ATTR, 22.0% AL, 15.3% other forms) were included in August 2020 until February 2021 (mean age 71.2 ±11.3 years; 30% women). The median diagnostic delay between onset of symptoms and diagnosis was 9.0 (range: 2.5; 33.0) months. Local health care providers (HCPs) play a central role on the way to diagnosis. Diagnosis itself typically requires a clinical but not necessarily a university setting. In the treatment phase, the focus moves to the amyloidosis centre as primary contact and coordinator, with general practitioners (GPs) acting predominantly as a contact point in crisis and link to additional services. About half of patients reported impaired quality of life and one third suffering from anxiety and depressed mood, respectively. The majority of patients talk about their concerns with close caregivers and local HCPs. Advance care planning is a relevant, yet insufficiently met need.&#13;
&#13;
&#13;
Conclusion&#13;
The journey of patients with amyloidotic disease, their contact partners and needs at different stages were characterized in detail within the German health care system. An amyloidosis-specific care concept has to master the multitude of interfaces connecting the numerous treatment providers involved with the amyloidosis centre and GPs as key players. Telemedical approaches could be a promising and well-accepted option allowing optimal coordination and communication.</abstract>
    <parentTitle language="eng">PLOS ONE</parentTitle>
    <identifier type="issn">1932-6203</identifier>
    <identifier type="doi">10.1371/journal.pone.0297182</identifier>
    <enrichment key="opus_doi_flag">true</enrichment>
    <enrichment key="opus_import_data">{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:21:32Z","timestamp":1747196492463,"version":"3.40.5"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Interdisciplinary Center of Clinical Research W\u00fcrzburg","award":["Z-2_CSP-08"]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"&lt;jats:sec id=\"sec001\"&gt;\n&lt;jats:title&gt;Background&lt;\/jats:title&gt;\n&lt;jats:p&gt;Amyloidosis is a rare multi-system disorder associated with frequently delayed diagnosis, enormous disease burden and psychosocial distress.&lt;\/jats:p&gt;\n&lt;\/jats:sec&gt;\n&lt;jats:sec id=\"sec002\"&gt;\n&lt;jats:title&gt;Methods&lt;\/jats:title&gt;\n&lt;jats:p&gt;Systematic assessment of needs was performed by a subtype-spanning questionnaire-based survey within the &lt;jats:sub&gt;A&lt;\/jats:sub&gt;MY-NEED&lt;jats:sub&gt;S&lt;\/jats:sub&gt; research and care program.&lt;\/jats:p&gt;\n&lt;\/jats:sec&gt;\n&lt;jats:sec id=\"sec003\"&gt;\n&lt;jats:title&gt;Results&lt;\/jats:title&gt;\n&lt;jats:p&gt;118 patients with proven amyloidosis (62.7% ATTR, 22.0% AL, 15.3% other forms) were included in August 2020 until February 2021 (mean age 71.2 \u00b111.3 years; 30% women). The median diagnostic delay between onset of symptoms and diagnosis was 9.0 (range: 2.5; 33.0) months. Local health care providers (HCPs) play a central role on the way to diagnosis. Diagnosis itself typically requires a clinical but not necessarily a university setting. In the treatment phase, the focus moves to the amyloidosis centre as primary contact and coordinator, with general practitioners (GPs) acting predominantly as a contact point in crisis and link to additional services. About half of patients reported impaired quality of life and one third suffering from anxiety and depressed mood, respectively. The majority of patients talk about their concerns with close caregivers and local HCPs. Advance care planning is a relevant, yet insufficiently met need.&lt;\/jats:p&gt;\n&lt;\/jats:sec&gt;\n&lt;jats:sec id=\"sec004\"&gt;\n&lt;jats:title&gt;Conclusion&lt;\/jats:title&gt;\n&lt;jats:p&gt;The journey of patients with amyloidotic disease, their contact partners and needs at different stages were characterized in detail within the German health care system. An amyloidosis-specific care concept has to master the multitude of interfaces connecting the numerous treatment providers involved with the amyloidosis centre and GPs as key players. Telemedical approaches could be a promising and well-accepted option allowing optimal coordination and communication.&lt;\/jats:p&gt;\n&lt;\/jats:sec&gt;","DOI":"10.1371\/journal.pone.0297182","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T17:29:36Z","timestamp":1716226176000},"page":"e0297182","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Single German centre experience with patient journey and care-relevant needs in amyloidosis: The German AMY-NEEDS research and care program"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8540-7122","authenticated-orcid":true,"given":"Sandra Michaela","family":"Ihne-Schubert","sequence":"first","affiliation":[]},{"given":"Maria","family":"Leberzammer","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6756-2267","authenticated-orcid":true,"given":"Marcel","family":"Weidgans","sequence":"additional","affiliation":[]},{"given":"Stefan","family":"Frantz","sequence":"additional","affiliation":[]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[]},{"given":"Stefan","family":"Knop","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9546-880X","authenticated-orcid":true,"given":"Torben","family":"Schubert","sequence":"additional","affiliation":[]},{"given":"Tanja","family":"Bratan","sequence":"additional","affiliation":[]},{"given":"Stefan","family":"St\u00f6rk","sequence":"additional","affiliation":[]},{"given":"Silke","family":"Neuderth","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"pone.0297182.ref001","article-title":"Amyloidosis in Heart Failure","author":"S Ihne","year":"2019","journal-title":"Curr Heart Fail Rep"},{"key":"pone.0297182.ref002","first-page":"159","article-title":"Amyloidosis\u2014the diagnosis and treatment of an underdiagnosed disease","volume":"117","author":"S Ihne","year":"2020","journal-title":"Dtsch Arztebl Int 2020"},{"key":"pone.0297182.ref003","article-title":"Diagnostic delay and characterization of the clinical prodrome in al amyloidosis among 1,523 us adults diagnosed between 2001 and 2019","author":"LL Hester","year":"2021","journal-title":"Eur J Haematol"},{"issue":"10","key":"pone.0297182.ref004","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","article-title":"Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium","volume":"32","author":"I Lousada","year":"2015","journal-title":"Adv Ther"},{"issue":"1","key":"pone.0297182.ref005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","article-title":"Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review","volume":"10","author":"MH Rozenbaum","year":"2021","journal-title":"Cardiol Ther"},{"key":"pone.0297182.ref006","article-title":"Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement","author":"S Oubari","year":"2021","journal-title":"Eur J Haematol"},{"issue":"11","key":"pone.0297182.ref007","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2217\/cer-2021-0071","article-title":"Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy","volume":"10","author":"MH Rozenbaum","year":"2021","journal-title":"J Comp Eff Res"},{"issue":"22","key":"pone.0297182.ref008","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20","volume":"146","author":"A Ioannou","year":"2022","journal-title":"Years. Circulation"},{"issue":"24","key":"pone.0297182.ref009","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis","volume":"133","author":"JD Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"1","key":"pone.0297182.ref010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"D Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0297182.ref011","doi-asserted-by":"crossref","first-page":"27","DOI":"10.17925\/HI.2023.17.1.27","article-title":"Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy","volume":"17","author":"A Ioannou","year":"2023","journal-title":"Heart Int"},{"issue":"4","key":"pone.0297182.ref012","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis","volume":"139","author":"SD Solomon","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"pone.0297182.ref013","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"MD Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"pone.0297182.ref014","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.amjcard.2022.10.014","article-title":"Overview of Current and Emerging Therapies for Amyloid Transthyretin Cardiomyopathy","volume":"185Suppl 1","author":"MS Maurer","year":"2022","journal-title":"Am J Cardiol"},{"issue":"13","key":"pone.0297182.ref015","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"Vutrisiran: First Approval","volume":"82","author":"SJ Keam","year":"2022","journal-title":"Drugs"},{"issue":"11","key":"pone.0297182.ref016","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"MS Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0297182.ref017","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA","volume":"136","author":"G Palladini","year":"2020","journal-title":"Blood"},{"unstructured":"Forschungsgruppe Wahlen Telefonfeld GmbH. Versichertenbefragung der Kassen\u00e4rztlichen Bundesvereinigung 2021\u2014Ergebnisse einer repr\u00e4sentativen Bev\u00f6lkerungsumfrage (M\u00e4rz\/April 2021). 2021.","key":"pone.0297182.ref018"},{"key":"pone.0297182.ref019","article-title":"Light Chain (AL) Amyloidosis: The Journey to Diagnosis","author":"KL McCausland","year":"2017","journal-title":"Patient"},{"author":"S Ihne","journal-title":"(under review)","article-title":"Needs of amyloidosis patients and their care providers: Design &amp; first results of the AMY-NEEDS research and care program","key":"pone.0297182.ref020"},{"key":"pone.0297182.ref021","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/978-3-531-19397-7_10","article-title":"Auswertung von Fokusgruppen mittels Zusammenfassung zentraler Diskussionsaspekte","author":"M. Ruddat","year":"2012","journal-title":"Fokusgruppen in der empirischen Sozialwissenschaft\u2014Von der Konzeption bis zur Auswertung VS Verlag f\u00fcr Sozialwissenschaften"},{"issue":"1","key":"pone.0297182.ref022","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2307\/1913643","article-title":"Regression Quantiles","volume":"46","author":"R Koenker","year":"1978","journal-title":"Econometrica"},{"issue":"1","key":"pone.0297182.ref023","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13023-021-01706-7","article-title":"Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups","volume":"16","author":"D Rintell","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"pone.0297182.ref024","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s12350-021-02575-0","article-title":"The prevalence of TTR cardiac amyloidosis among patients undergoing bone scintigraphy","volume":"28","author":"M Bianco","year":"2021","journal-title":"J Nucl Cardiol"},{"issue":"3","key":"pone.0297182.ref025","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/13506129.2016.1208081","article-title":"Depression and anxiety in patients with AL amyloidosis as assessed by the SF-36 questionnaire: experience in 1226 patients()","volume":"23","author":"J Shu","year":"2016","journal-title":"Amyloid"},{"issue":"3","key":"pone.0297182.ref026","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s00392-018-1348-6","article-title":"Symptom patterns and clinical outcomes in women versus men with systolic heart failure and depression","volume":"108","author":"SM Piepenburg","year":"2019","journal-title":"Clin Res Cardiol"},{"issue":"1\u20132","key":"pone.0297182.ref027","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.psychres.2014.07.054","article-title":"Differences in the developmental patterns of depression with and without additional somatic symptoms","volume":"220","author":"B Silverstein","year":"2014","journal-title":"Psychiatry Res"},{"issue":"5\u20136","key":"pone.0297182.ref028","first-page":"733","article-title":"[Prevalence of depressive symptoms and diagnosed depression among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]","volume":"56","author":"MA Busch","year":"2013","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"1","key":"pone.0297182.ref029","first-page":"77","article-title":"[Mental disorders in the general population: Study on the health of adults in Germany and the additional module mental health (DEGS1-MH)]","volume":"85","author":"F Jacobi","year":"2014","journal-title":"Nervenarzt"},{"issue":"20","key":"pone.0297182.ref030","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/jama.2017.5706","article-title":"Management of Depression in Older Adults: A Review","volume":"317","author":"RM Kok","year":"2017","journal-title":"JAMA"},{"issue":"9","key":"pone.0297182.ref031","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jagp.2018.05.001","article-title":"Major Depression and Subthreshold Depression among Older Adults Receiving Home Care","volume":"26","author":"X Xiang","year":"2018","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"pone.0297182.ref032","first-page":"e93","article-title":"A Systematic Review of Older Adults\u2019 Attitudes Towards Depression and Its Treatment","volume":"60","author":"P Nair","year":"2020","journal-title":"Gerontologist"},{"issue":"2","key":"pone.0297182.ref033","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40120-018-0106-z","article-title":"Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers","volume":"7","author":"M Stewart","year":"2018","journal-title":"Neurol Ther"},{"issue":"1","key":"pone.0297182.ref034","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13023-021-01812-6","article-title":"Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy","volume":"16","author":"L Magliano","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"pone.0297182.ref035","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jamda.2018.09.014","article-title":"Interventions Guiding Advance Care Planning Conversations: A Systematic Review","volume":"20","author":"JC Fahner","year":"2019","journal-title":"J Am Med Dir Assoc"},{"unstructured":"Schaeffer D, Berens, E.-M., Gille, S., Griese, L., Klinger, J., de Sombre, S., et al. Gesundheitskompetenz der Bevo\u00f6lkerung in Deutschland\u2014vor und wa\u00f6hrend der Corona Pandemie: Ergebnisse des HLS-GER 2, Bielefeld: Interdisziplina\u00f6res Zentrum fu\u00f6r Gesundheitskompetenzforschung (IZGK), Universita\u00f6t Bielefeld. 2021.","key":"pone.0297182.ref036"},{"issue":"18","key":"pone.0297182.ref037","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0735-1097(21)02010-6","article-title":"Addressing Barriers to Amyloidosis Management: A practice assessment of clinical gaps","volume":"77","author":"MS J Harris","year":"2021","journal-title":"JACC"},{"issue":"1","key":"pone.0297182.ref038","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40119-019-00160-8","article-title":"Diagnosis of Amyloidosis: A Survey of Current Awareness and Clinical Challenges Among Cardiologists in Switzerland","volume":"9","author":"D. Mircsof","year":"2020","journal-title":"Cardiol Ther"},{"key":"pone.0297182.ref039","doi-asserted-by":"crossref","first-page":"11795468211015230","DOI":"10.1177\/11795468211015230","article-title":"Best Practices in Specialized Amyloidosis Centers in the United States: A Survey of Cardiologists, Nurses, Patients, and Patient Advocates","volume":"15","author":"J Nativi-Nicolau","year":"2021","journal-title":"Clin Med Insights Cardiol"},{"issue":"1","key":"pone.0297182.ref040","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.2196\/cardio.9936","article-title":"HerzMobil, an Integrated and Collaborative Telemonitoring-Based Disease Management Program for Patients With Heart Failure: A Feasibility Study Paving the Way to Routine Care","volume":"2","author":"E Ammenwerth","year":"2018","journal-title":"JMIR Cardio"},{"issue":"1","key":"pone.0297182.ref041","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1161\/CIRCHEARTFAILURE.111.962969","article-title":"Mode of action and effects of standardized collaborative disease management on mortality and morbidity in patients with systolic heart failure: the Interdisciplinary Network for Heart Failure (INH) study","volume":"5","author":"CE Angermann","year":"2012","journal-title":"Circ Heart Fail"},{"issue":"4","key":"pone.0297182.ref042","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ejhf.252","article-title":"Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling","volume":"17","author":"G Guder","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"pone.0297182.ref043","first-page":"773","article-title":"[Evidence-based disease management in patients with heart failure (HeartNetCare-HF Wurzburg)]","volume":"134","author":"S Stork","year":"2009","journal-title":"Dtsch Med Wochenschr"},{"issue":"3","key":"pone.0297182.ref044","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1161\/STROKEAHA.118.023779","article-title":"Telemedicine for Follow-Up of Rare Neurological Disease","volume":"50","author":"J Walsh","year":"2019","journal-title":"Stroke"},{"key":"pone.0297182.ref045","doi-asserted-by":"crossref","first-page":"117221","DOI":"10.1016\/j.jns.2020.117221","article-title":"Application of telehealth for comprehensive Creutzfeldt-Jakob disease surveillance in the United Kingdom","volume":"420","author":"N Watson","year":"2021","journal-title":"J Neurol Sci"},{"issue":"6","key":"pone.0297182.ref046","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/ejhf.2823","article-title":"Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study","volume":"25","author":"G Tini","year":"2023","journal-title":"Eur J Heart Fail"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0297182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T17:30:22Z","timestamp":1716226222000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0297182"}},"subtitle":[],"editor":[{"given":"Vincenzo","family":"Lionetti","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0297182","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2024,5,20]]}}}</enrichment>
    <enrichment key="local_crossrefDocumentType">journal-article</enrichment>
    <enrichment key="local_crossrefLicence">http://creativecommons.org/licenses/by/4.0/</enrichment>
    <enrichment key="local_import_origin">crossref</enrichment>
    <enrichment key="local_doiImportPopulated">PersonEditorFirstName_1,PersonEditorLastName_1,PersonAuthorFirstName_1,PersonAuthorLastName_1,PersonAuthorIdentifierOrcid_1,PersonAuthorFirstName_2,PersonAuthorLastName_2,PersonAuthorFirstName_3,PersonAuthorLastName_3,PersonAuthorIdentifierOrcid_3,PersonAuthorFirstName_4,PersonAuthorLastName_4,PersonAuthorFirstName_5,PersonAuthorLastName_5,PersonAuthorFirstName_6,PersonAuthorLastName_6,PersonAuthorFirstName_7,PersonAuthorLastName_7,PersonAuthorIdentifierOrcid_7,PersonAuthorFirstName_8,PersonAuthorLastName_8,PersonAuthorFirstName_9,PersonAuthorLastName_9,PersonAuthorFirstName_10,PersonAuthorLastName_10,PublisherName,TitleMain_1,Language,TitleAbstract_1,TitleParent_1,Issue,Volume,PublishedYear,IdentifierIssn,Enrichmentlocal_crossrefLicence</enrichment>
    <enrichment key="opus.source">doi-import</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>Creative Commons - CC BY - Namensnennung 4.0 International</licence>
    <author>Sandra Michaela Ihne-Schubert</author>
    <author>Maria Leberzammer</author>
    <author>Marcel Weidgans</author>
    <author>Stefan Frantz</author>
    <author>Hermann Einsele</author>
    <author>Stefan Knop</author>
    <author>Torben Schubert</author>
    <author>Tanja Bratan</author>
    <author>Stefan Störk</author>
    <author>Silke Neuderth</author>
    <collection role="institutes" number="ifas">Institut für Angewandte Sozialwissenschaften (IFAS)</collection>
  </doc>
</export-example>
